CC
NUVB icon

Clearline Capital’s Nuvation Bio NUVB Stock Holding History

Clearline Capital’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-436,437
Closed -$999K – 135
2024
Q3 		$999K Sell
436,437
-800
-0.2% -$2.44K 0.04% 116
2024
Q2 		$1.28M Hold
437,237
– – 0.04% 113
2024
Q1 		$1.59M Sell
437,237
-57,269
-12% -$110K 0.08% 93
2023
Q4 		$747K Hold
494,506
– – 0.05% 85
2023
Q3 		$663K Hold
494,506
– – 0.06% 110
2023
Q2 		$890K Hold
494,506
– – 0.05% 90
2023
Q1 		$821K Hold
494,506
– – 0.12% 79
2022
Q4 		$949K Hold
494,506
– – 0.17% 87
2022
Q3 		$1.11M Hold
494,506
– – 0.13% 97
2022
Q2 		$1.6M Hold
494,506
– – 0.21% 77
2022
Q1 		$2.6M Sell
494,506
-33,271
-6% -$187K 0.3% 74
2021
Q4 		$4.27M Buy
527,777
+141,836
+37% +$1.3M 0.47% 54
2021
Q3 		$3.84M Buy
385,941
+165,137
+75% +$1.5M 0.36% 61
2021
Q2 		$2.06M Buy
220,804
+196,813
+820% +$2.24M 0.31% 69
2021
Q1 		$251K Buy
+23,991
New +$268K 0.03% 107

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Clearline Capital's NUVB Position: Q4 2024 in Review

Clearline Capital sold out of Nuvation Bio (NUVB) in Q4 2024, closing a stake of 436,437 shares — an estimated $999K sold.

Clearline Capital first reported a position in NUVB in Q1 2021 and held it in 15 quarters. The position peaked at $4.27M in Q4 2021. 160 funds tracked by Wall St. Rank hold NUVB as of Q4 2024.

  • Clearline Capital reported no remaining Nuvation Bio position as of Q4 2024 after selling out during the quarter.
  • Clearline Capital sold 436,437 Nuvation Bio shares in Q4 2024, an estimated $999K.
  • Clearline Capital first reported a position in Nuvation Bio in Q1 2021 and held it in 15 quarters.
  • Clearline Capital's Nuvation Bio position peaked at $4.27M in Q4 2021.
  • 160 funds tracked by Wall St. Rank held Nuvation Bio as of Q4 2024.

Based on Clearline Capital's 13F filing for Q4 2024, filed 14 Feb 2025.